Yahoo
NasdaqCM - Delayed Quote USD

BioVie Inc. (BIVI)

1.6800 +0.0300 (+1.82%)
At close: May 1 at 4:00:01 PM EDT
1.7300 +0.0500 (+2.98%)
After hours: May 1 at 7:17:16 PM EDT
Chart Range Bar
Loading chart for BIVI
  • Previous Close 1.6500
  • Open 1.6750
  • Bid 1.6000 x 100
  • Ask 1.7200 x 100
  • Day's Range 1.6523 - 1.7800
  • 52 Week Range 1.0600 - 13.2000
  • Volume 177,298
  • Avg. Volume 84,935
  • Market Cap (intraday) 12.668M
  • Beta (5Y Monthly) 0.56
  • PE Ratio (TTM) --
  • EPS (TTM) -3.2800
  • Earnings Date (est.) May 11, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

bioviepharma.com

13

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: BIVI

Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BIVI
44.83%
S&P 500 (^GSPC)
5.62%

1-Year Return

BIVI
80.51%
S&P 500 (^GSPC)
29.01%

3-Year Return

BIVI
99.78%
S&P 500 (^GSPC)
73.47%

5-Year Return

BIVI
99.90%
S&P 500 (^GSPC)
72.92%

Earnings Trends: BIVI

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -5.09M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-5M
-4M
-3M
-2M
-1M
0

Statistics: BIVI

View More

Valuation Measures

Annual
As of 5/1/2026
  • Market Cap

    12.67M

  • Enterprise Value

    -7.56M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.66

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -47.20%

  • Return on Equity (ttm)

    -80.74%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -17.48M

  • Diluted EPS (ttm)

    -3.2800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    20.54M

  • Total Debt/Equity (mrq)

    1.63%

  • Levered Free Cash Flow (ttm)

    -8.28M

Compare To: BIVI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: BIVI

Fair Value

1.6800 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: